MAINZ, Germany, December 31, 2020 — BioNTech SE (Nasdaq: BNTX) today wants to express its thanks and gratitude not only to its employees but also to the many partners who have assisted the company in successfully developing a vaccine for COVID-19. BioNTech acknowledges that without the tireless effort from its’ employees and partners, who have played a pivotal role in this effort, it would not have been able to achieve this historic company milestone, a journey which only began in early 2020. Data from its Phase 3 study have demonstrated that the vaccine is well-tolerated and 95% effective in preventing COVID-19. The vaccine has already received conditional marketing authorizations as well as emergency use authorizations in more than 45 countries around the world, including the United States and the European Union.
BioNTech’s employees have made a significant contribution to this initiative, working around the clock to harness the power of mRNA and apply it to this effort of fighting against the devastating pandemic. In addition, our partner companies and organizations have provided the company with research expertise, critical supply support, and valuable insights and assistance throughout the development and trial process. Without them, achieving this result only 11 months after the initiation of Project Lightspeed would not have been possible.
“To address a global challenge like COVID-19, we have undertaken a worldwide effort to develop a well-tolerated and effective vaccine as quickly as science and cutting-edge technology will allow,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Despite the damage caused by the virus, I have been inspired each day by the spirit of collaboration and scientific discovery. It is one of the greatest honors of my life to be involved in this effort and to play a role in helping the world regain a sense of normality. I would like to thank each and every person that helped make this a reality.”
BioNTech’s management and employees appreciate the relentlessly support of many companies. A full list of BioNTech’s partners supporting the COVID-19 project can be found below and at this link.
Our Partners:
| A-C | D-L | M-P | Q-Z |
| A&C Biobuffer | D-HCC Dopamine Healthcare Communication | Maetrics | QIAGEN |
| Acuitas | Dätwyler Holding | MACHEREY-NAGEL | Ragon Institute of MGH, MIT and Harvard |
| Admedicum | Delpharm | Marble Pharma Consult | Ramsay Pharma |
| Agilent Technologies Sales & Services | Dermapharm | Medidata | RD-Biotech |
| Alexis Carpenter Consulting | DHL | medwiss-extern | Real Life Sciences |
| ALFA Chemicals | Discovery Life Sciences | Merck | Regeneron |
| Almac Clinical Services | Dr. Liebscher Consulting | Merck Chemicals | Rentschler |
| Applied Critical Fluids | Dunn Labortechnik | Meso Scale Diagnostics | Repligen Corporation |
| Aristo Group | Entourage Pharma Consulting | Miltenyi Biotec | Sartorius Lab Instruments |
| auceris | Eppendorf Vertrieb Deutschland | mpütranslations | Sartorius Stedim Biotech |
| Avanti Polar Lipids | Eurobio Scientific | Mundicare | Schott |
| Avia Pharma | Eurofins Genomics Germany | nerbe plus | Siegfried |
| Baxter | Evonik Industries | New England Biolabs | Siemens |
| Becton Dickinson | Finsbury Glover Hering Corporation | National Institutes of Health (NIH | Sigma-Aldrich Chemie |
| Bexon Clinical Consulting | Fisher Scientific | Novartis | Sino Biological Europe |
| Biaffin | Fosun Pharma | ONE LOGIC | Sinus Event-Technik |
| BioCat | Fraunhofer-Institut für Techno- und Wirtschaftsmathematik ITWM | ORIGIO Clinical Monitoring | SOMI Solutions |
| BioLegend Europe | FreshFields Bruckhaus Deringer | Osborne Clarkeg | Staburo |
| Biomay | Gowling WLG | Panhans Pharma Consul | Stephenson Harwood |
| Biotrend Chemikalien | Granzer Regulatory Consulting & Service | Paul Hastings | Stevenato Group |
| Biozol Diagnostica Vertrieb | Greiner Bio-One | Peak Scientific | SyroCon Consulting |
| Brand Institute | GlaxoSmithKline (GSK) | Pfizer | TCW |
| Carl Roth | Heidrick & Struggles | Phaidon International | Tecan Deutschland |
| Catalent | Hölzel Diagnostika Handels | PharmaCentaur | Tenthpin Management |
| CG Pharma | Horváth & Partner | PHARM-SOFT Dr. B. Rodu | Thermo Fisher Scientific |
| Chemgineering | ICON | PHMR | THERON Management Advisors |
| Choate Hall & Stewart | Informa Pharma Intelligence | Phoenix-Apotheke Mainz | Topmedicare |
| CMS Legal Services | Instadeep | Pixilicious Enterprises | TriLink BioTechnologies |
| Cognigy | K-Recruiting | Plan@ IT Services | TriRadial Solutions |
| Cole-Parmer | Kerafast | Polymun | TRON |
| Consulimus | Kissel Pharma Consulting | portvier | Trophic Communications |
| Consultants | Korn Ferry | Powell Gilbert | Universitätsklinikum Frankfurt |
| Corning | Knauer | Precision Bioservices | UniversitätsKlinikum Heidelberg |
| Covington | LGC Genomics | Precision for Medicin | VisMederi |
| CRB Group | Life Technologies (Thermo Fisher Scientific) | Profishop-Bremee | VWR International |
| Croda International | LKF-Laboratorium für Klinische Forschung | ProfiLab24 | Waters |
| CRS Clinical Research Services Mannheim | Progedo | WE Communications | |
| Progressive Recruitment | World Courrier | ||
| pure 11 | ZSP Patentanwälte | ||
| PriceWaterhouseCoopers (PwC) |
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.
BioNTech Contacts:
Media Relations
Jasmina Alatovic
+49 6131 9084-0
Media@biontech.de
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de
